Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 107,738 shares, a growth of 93.0% from the January 15th total of 55,812 shares. Based on an average daily trading volume, of 2,264,204 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 2,264,204 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Several research firms have commented on BAYRY. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 20th. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Three equities research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 0.6%

Shares of BAYRY stock opened at $13.58 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. Bayer Aktiengesellschaft has a twelve month low of $5.30 and a twelve month high of $13.98. The company’s 50-day moving average price is $11.88 and its 200-day moving average price is $9.43. The stock has a market cap of $53.37 billion, a price-to-earnings ratio of -150.87, a PEG ratio of 4.85 and a beta of 0.68.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.